Company news
Marker Therapeutics, Inc. (NASDAQ:MRKR) news
Marker Therapeutics, Inc. news releases on 6ix. Latest, Mar 18, 2026: Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Press releases & updates
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
March 17, 2026
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 18, 2026
Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology
January 26, 2026
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
January 5, 2026
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 14, 2025
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
November 5, 2025
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
November 3, 2025
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
October 6, 2025
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
August 28, 2025
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
August 26, 2025
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
July 30, 2025
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
June 17, 2025
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
May 20, 2025
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
May 19, 2025
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
April 1, 2025
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
March 31, 2025
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 25, 2025
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
December 18, 2024
Marker Therapeutics Announces $16.1 Million Private Placement
December 18, 2024
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
December 16, 2024
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
December 9, 2024
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
November 25, 2024
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 13, 2024
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
August 11, 2024
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 14, 2024
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
April 7, 2024
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
March 24, 2024
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 21, 2024
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
January 21, 2024
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
January 7, 2024
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
December 20, 2023
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
December 10, 2023
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 8, 2023
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
September 10, 2023
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 29, 2023
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
August 16, 2023
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 13, 2023
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
August 6, 2023
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
July 25, 2023
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
July 9, 2023
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
June 25, 2023
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
June 11, 2023
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
May 30, 2023
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
May 7, 2023
Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™
April 30, 2023
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
March 21, 2023
Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
December 12, 2022
Marker Therapeutics Announces FDA Clearance of IND for MT-601, its Six-Antigen T Cell Therapy for the Treatment of Pancreatic Cancer
November 21, 2022
Marker Therapeutics Reports Q3 2022 Operating and Financial Results
November 9, 2022